Combining Traditional Systemic and Biologic Therapies for Psoriasis

Seminars in Cutaneous Medicine and Surgery

Volumn 29, Issue 1, 2010, Pages 67-69

  Heffernan, Michael P ^a  

^a Clinical Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISONE; PSORALEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETINOID; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; LUPUS LIKE SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; PHOTOTHERAPY; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; REVIEW; SKIN CANCER; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; PHOTOTHERAPY; PSORIASIS;

EID: 77951602422     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2010.03.003     Document Type: Review

References (21)

1. Krueger G.G., Koo J., Lebwohl M., et al. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137 (2001) 280-284
2. Koo J., Lee E., Lee C.S., et al. Psoriasis. J Am Acad Dermatol 50 (2004) 613-622
3. Hearn R.M., Kerr A.C., Rahim K.F., et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 159 (2008) 931-935
4. Lim J.L., and Stern R.S. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol 124 (2005) 505-513
5. Stern R.S., Leibman E.J., and Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 90 (1998) 1278-1284
6. Marcil I., and Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: Nested cohort crossover study. Lancet 358 (2001) 1042-1045
7. Nijsten T.E.C., and Stern R.S. Oral retinoid use reduced cutaneous squamous cell carcinoma risk in patients with psoriasis treat with psoralen-UVA: A nested cohort study. J Am Acad Dermatol 49 (2003) 644-650
8. Stern R.S. Lymphoma risk in psoriasis. Arch Dermatol 142 (2006) 1132-1135
9. Stern R.S., Khahn N.T., and Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 336 (1997) 1041-1045
10. Wolfe F., and Michaud K. Biologic treatment of rheumatoid arthritis and risk of malignancy: Analyses from a large US observational study. Arch Rheum 56 (2007) 2886-2895
11. Koo J.Y., Bagel J., Sweetser M.T., et al. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: Results from an open-label, multicenter study. J Drugs Dermatol 5 (2006) 623-628
12. Gisondi P., Del Giglio M., Cotena C., et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: A 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 158 (2009) 1345-1349
13. Legat F.J., Hofer A., Wackernagel A., et al. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 143 (2007) 1016-1022
14. Kircik L., Bagel J., Korman N., et al., Unite Study Group. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): Efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 7 (2008) 245-253
15. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol 120 (2003) 211-216
16. Magliocco M.A., Lozano A.M., Van Saders C., et al. An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept. J Drugs Dermatol 6 (2007) 424-427
17. Giannitti C., Benucci M., Caporali R., et al. Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol 22 (2009) 543-546
18. Warren R.B., and Griffiths C.E. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine [review]. Clin Dermatol 26 (2008) 438-447
19. Genovese M.C., Cohen S., Moreland L., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arth Rheum 50 (2004) 1412-1419
20. Orencia. Package insert (2005), Bristol-Myers Squibb Co, Princeton, NJ
21. Krell J.M. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol 54 (2006) 1099-1101